Analyst Interview – Sucampo Pharmaceuticals

Analyst Interview – Sucampo Pharmaceuticals

Christian Glennie, Healthcare Analyst at Edison, discusses the investment case for Sucampo Pharmaceuticals, a US-based pharmaceutical company, which recently obtained regulatory approval for an important new use of its constipation drug, Amitiza. The approval caused a major re-rating of the stock and Christian reviews further potential catalysts, the key challenges for Sucampo and his approach to valuing the company.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free